Abstract
RNA interference (RNAi) holds great promise as gene therapy approach against viral pathogens, including HIV-1. A specific anti-HIV-1 response can be induced via transfection of synthetic small interfering RNAs (siRNAs) or via intracellular transgene expression of short hairpin RNAs (shRNAs) or microRNAs (miRNAs). Both targeting of the viral mRNAs or the mRNAs for cellular co-factors that are required for viral replication have been shown successful in suppressing HIV-1 replication. However, like conventional mono-therapies, the use of a single anti-HIV-1 RNAi inducer results in the emergence of RNAi-escape mutants. To prevent viral escape, a combinatorial RNAi approach should be used in which multiple RNAi effectors against HIV-1 are simultaneously expressed. Although induced RNAi is able to trigger a robust and specific knockdown of virus replication, it is becoming apparent that RNAi therapeutics encounter difficulties concerning off-target effects, cellular toxicity and specific delivery to the right cells. This review covers the recent progress in combinatorial RNAi-based approaches against HIV-1 using lentiviral vectors as a delivery system. The potential for a clinical gene therapy application will be discussed.
Current Topics in Medicinal Chemistry
Title: Lentiviral Delivery of RNAi Effectors Against HIV-1
Volume: 9 Issue: 12
Author(s): Ying Poi Liu and Ben Berkhout
Affiliation:
Abstract: RNA interference (RNAi) holds great promise as gene therapy approach against viral pathogens, including HIV-1. A specific anti-HIV-1 response can be induced via transfection of synthetic small interfering RNAs (siRNAs) or via intracellular transgene expression of short hairpin RNAs (shRNAs) or microRNAs (miRNAs). Both targeting of the viral mRNAs or the mRNAs for cellular co-factors that are required for viral replication have been shown successful in suppressing HIV-1 replication. However, like conventional mono-therapies, the use of a single anti-HIV-1 RNAi inducer results in the emergence of RNAi-escape mutants. To prevent viral escape, a combinatorial RNAi approach should be used in which multiple RNAi effectors against HIV-1 are simultaneously expressed. Although induced RNAi is able to trigger a robust and specific knockdown of virus replication, it is becoming apparent that RNAi therapeutics encounter difficulties concerning off-target effects, cellular toxicity and specific delivery to the right cells. This review covers the recent progress in combinatorial RNAi-based approaches against HIV-1 using lentiviral vectors as a delivery system. The potential for a clinical gene therapy application will be discussed.
Export Options
About this article
Cite this article as:
Liu Poi Ying and Berkhout Ben, Lentiviral Delivery of RNAi Effectors Against HIV-1, Current Topics in Medicinal Chemistry 2009; 9 (12) . https://dx.doi.org/10.2174/156802609789630866
DOI https://dx.doi.org/10.2174/156802609789630866 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents on Proteases and Kinases as Anti-Infective Agents: A Review
Recent Patents on Anti-Infective Drug Discovery Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options
Current Pharmaceutical Biotechnology Nanoparticulate Drug Delivery System to Overcome the Limitations of Conventional Curcumin in the Treatment of Various Cancers: A Review
Drug Delivery Letters Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Antagonists of CCR4 as Immunomodulatory Agents
Current Topics in Medicinal Chemistry Is DNA Minor Groove Binding Crucial for Biological Activity of Triazoloacridinones with Cytotoxic and Antitumour Properties?
Letters in Drug Design & Discovery Biological Evidence for the Benefit of Green Tea and EGCG in Arthritis
Current Rheumatology Reviews Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications
Current Drug Targets Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Molecular Therapy Intervention Prospects in Prostate Cancer
Current Pharmaceutical Design Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology Targeted Delivery of Natural Bioactives and Lipid-nanocargos against Signaling Pathways Involved in Skin Cancer
Current Medicinal Chemistry Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Intracellular Signaling Pathways Modulated by Phenolic Compounds: Application for New Anti-Inflammatory Drugs Discovery
Current Medicinal Chemistry Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry